<DOC>
	<DOCNO>NCT01865110</DOCNO>
	<brief_summary>This study aim evaluate whether addition lenalidomide rituximab-maintenance improves progression free survival ( PFS ) compare standard rituximab maintenance induction treatment consist R-CHOP + R-HAD vs R-CHOP alone old patient ( ≥ 60 year old ) mantle cell lymphoma . The treatment consist two phase : induction treatment ( 3 R-CHOP21 + 3 cycle R-HAD28 alternate ) v 8 cycle R-CHOP21 ) follow maintenance treatment ( 13 cycle rituximab + 26 cycle lenalidomide vs 13 cycle rituximab ) .</brief_summary>
	<brief_title>R-CHOP + R-HAD v R-CHOP Followed Maintenance Lenalidomide + Rituximab v Rituximab Older Patients With MCL</brief_title>
	<detailed_description>This study aim evaluate whether addition lenalidomide rituximab-maintenance improves progression free survival ( PFS ) compare standard rituximab maintenance induction treatment consist R-CHOP + R-HAD versus R-CHOP alone old patient ( ≥ 60 year old ) mantle cell lymphoma . 643 patient randomized induction phase 433 maintenance phase . The treatment consist two phase : - induction treatment 3 cycle R-CHOP21 + 3 cycle R-HAD28 ( alternate ) versus 8 cycle R-CHOP21 alone - maintenance treatment 13 cycle rituximab every 8 week + 26 cycle lenalidomide every 4 week vs 13 cycle rituximab every 8 week . Patients follow 2.5 year last patient randomize maintenance final analysis . All subject complete discontinue maintenance treatment reason follow least 3 year his/her last study treatment administration maintenance period Second Primary Malignancies ( SPM ) . A long term follow-up progression/death do end period SPM data collection .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Signed informed consent form Biopsyproven MCL accord WHO classification ≥ 60 year age ineligible autologous transplant Ann Arbor stage IIIV Previously untreated ECOG PS ≤ 2 Male subject must : agree use condom sexual contact woman childbearing potential , even vasectomy , throughout lenalidomide therapy agree donate semen lenalidomide therapy . All subject must : understanding lenalidomide could potential teratogenic risk . agree abstain donate blood take lenalidomide therapy agree share study medication another person . counselled pregnancy precaution risk foetal exposure . Additional criterion randomization maintenance phase : CR , CRu PR induction treatment , determine per Cheson 1999 criterion During runin period 6 month start date first randomization trial : case direct randomization maintenance phase , patient must treat first line 68 cycle RCHOP . Female childbearing potential Any follow laboratory abnormality diagnosis , related lymphoma : Absolute neutrophils count &lt; 1,000 /mm3 Platelet count &lt; 75,000/mm3 AST/SGOT ALT/SGPT &gt; 3.0 UNL Serum total bilirubin &gt; 1.5 ULN ( except due Gilbert 's syndrome ) Calculated creatinine clearance ( CockcroftGault formula MDRD ) &lt; 30 mL / min Central Nervous System involvement lymphoma Contraindication medical DVT prophylaxis patient high risk DVT Prior history malignancy MCL unless subject free disease ≥ 5 year . Exceptions include follow : Basal cell carcinoma Squamous cell carcinoma skin Carcinoma situ cervix breast Incidental histologic find prostate cancer ( TNM stage T1a T1b ) . Any serious medical condition , laboratory abnormality psychiatric illness would prevent patient receive study medication plan . Seropositivity human immunodeficiency virus study entry Seropositivity hepatitis C virus study entry , Active viral infection hepatitis B virus study entry : HBsAg positive HBsAg negative , antiHBs positive antiHBc positive Uncontrolled illness include , limited : Active infection require parenteral antibiotic . Uncontrolled diabetes mellitus Chronic symptomatic congestive heart failure ( Class NYHA III IV ) . Unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month Clinically significant cardiac arrhythmia symptomatic require treatment , asymptomatic sustain ventricular tachycardia . Prior ≥ Grade 3 allergic hypersensitivity thalidomide . Prior ≥ Grade 3 rash desquamating ( blister ) rash take thalidomide . Known antimurine antibody ( HAMA ) reactivity know hypersensitivity murine antibody . Subjects ≥ Grade 2 neuropathy . Prior use lenalidomide Participation another clinical trial within three week randomization study Additional criterion randomization maintenance phase : SD PD induction treatment determine per Cheson 1999 criterion Patient treat induction immunochemotherapy 68 cycle RCHOP21 23 cycle RCHOP21 / 23 cycle RHAD28 ( alternate ) Patients serious underlie medical condition , could impair ability receive maintenance treatment Calculated creatinine clearance &lt; 30 mL / min ANC &lt; 1,000 cells/mm³ Platelet count &lt; 50,000 cells/mm³</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>RCHOP</keyword>
	<keyword>RHAD</keyword>
	<keyword>rituximab</keyword>
	<keyword>lenalidomide</keyword>
</DOC>